Ajinomoto Althea: Lilly to Invest $72M in U.S. Insulin Manufacture

Eli Lilly and Co. plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an existing insulin vial filling line and allows Lilly to expand insulin production, including Humalog and Humulin, and upgrade to new technology and prepare for its insulin pipeline